Literature DB >> 10358152

CD19 amplifies B lymphocyte signal transduction by regulating Src-family protein tyrosine kinase activation.

M Fujimoto1, J C Poe, P J Jansen, S Sato, T F Tedder.   

Abstract

Ligation of the B cell Ag receptor (BCR) induces cellular activation by stimulating Src-family protein tyrosine kinases (PTKs) to phosphorylate members of the BCR complex. Subsequently, Src-family PTKs, particularly Lyn, are proposed to phosphorylate and bind CD19, a cell-surface costimulatory molecule that regulates mature B cell activation. Herein, we show that B cells from CD19-deficient mice have diminished Lyn kinase activity and BCR phosphorylation following BCR ligation. Tyrosine phosphorylation of other Src-family PTKs was also decreased in CD19-deficient B cells. In wild-type B cells, CD19 was constitutively complexed with Vav, Lyn, and other Src-family PTKs, with CD19 phosphorylation and its associations with Lyn and Vav increased after BCR ligation. Constitutive CD19/Lyn/Vav complex signaling may therefore be responsible for the establishment of baseline signaling thresholds in B cells before Ag receptor ligation, in addition to accelerating signaling following BCR engagement or other transmembrane signals. In vitro kinase assays using purified CD19 and purified Lyn revealed that the kinase activity of Lyn was significantly increased when coincubated with CD19. Thus, constitutive and induced CD19/Lyn complexes are likely to regulate basal signaling thresholds and BCR signaling by amplifying the kinase activity of Lyn and other Src-family PTKs. These in vivo and in vitro findings demonstrate a novel mechanism by which CD19 regulates signal transduction in B lymphocytes. The absence of this CD19/Src-family kinase amplification loop may account for the hyporesponsive phenotype of CD19-deficient B cells.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10358152

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  31 in total

Review 1.  The role of complement in the acquired immune response.

Authors:  C H Nielsen; E M Fischer; R G Leslie
Journal:  Immunology       Date:  2000-05       Impact factor: 7.397

Review 2.  Regulatory and signaling properties of the Vav family.

Authors:  X R Bustelo
Journal:  Mol Cell Biol       Date:  2000-03       Impact factor: 4.272

3.  Vav-2 controls NFAT-dependent transcription in B- but not T-lymphocytes.

Authors:  G M Doody; D D Billadeau; E Clayton; A Hutchings; R Berland; S McAdam; P J Leibson; M Turner
Journal:  EMBO J       Date:  2000-11-15       Impact factor: 11.598

Review 4.  Role of CD19 signal transduction in B cell biology.

Authors:  Robert H Carter; Yue Wang; Stephen Brooks
Journal:  Immunol Res       Date:  2002       Impact factor: 2.829

Review 5.  Molecular and cellular mechanisms of CLL: novel therapeutic approaches.

Authors:  Lisa Pleyer; Alexander Egle; Tanja Nicole Hartmann; Richard Greil
Journal:  Nat Rev Clin Oncol       Date:  2009-06-02       Impact factor: 66.675

6.  Balanced Vav2 GEF activity regulates neurite outgrowth and branching in vitro and in vivo.

Authors:  Myung-soon Moon; Timothy M Gomez
Journal:  Mol Cell Neurosci       Date:  2010-03-16       Impact factor: 4.314

7.  The transmembrane tyrosine of micro-heavy chain is required for BCR destabilization and entry of antigen into clathrin-coated vesicles.

Authors:  Jin Hyang Kim; Jennifer A Rutan; Barbara J Vilen
Journal:  Int Immunol       Date:  2007-11-01       Impact factor: 4.823

8.  CD21 signaling via C3 regulates Purkinje cell protein 4 expression.

Authors:  Amanda C Jacobson; Janis J Weis; John H Weis
Journal:  Mol Immunol       Date:  2009-02-07       Impact factor: 4.407

9.  Bispecific and trispecific killer cell engagers directly activate human NK cells through CD16 signaling and induce cytotoxicity and cytokine production.

Authors:  Michelle K Gleason; Michael R Verneris; Deborah A Todhunter; Bin Zhang; Valarie McCullar; Sophia X Zhou; Angela Panoskaltsis-Mortari; Louis M Weiner; Daniel A Vallera; Jeffrey S Miller
Journal:  Mol Cancer Ther       Date:  2012-10-17       Impact factor: 6.261

10.  CD22 Promotes B-1b Cell Responses to T Cell-Independent Type 2 Antigens.

Authors:  Karen M Haas; Kristen L Johnson; James P Phipps; Cardinal Do
Journal:  J Immunol       Date:  2018-01-26       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.